Promising Medical Stocks To Keep An Eye On - March 10th

Key Points

• Hims & Hers (HIMS), UnitedHealth Group (UNH) and Vertex Pharmaceuticals (VRTX) are MarketBeat’s three medical stocks to watch, chosen because they had the highest dollar trading volume among medical stocks in recent days.
• Hims & Hers operates a telehealth platform for mental health, sexual health, dermatology and primary care and recently surged on news of a deal with Novo Nordisk.
• UnitedHealth is a diversified health insurer and services company across UnitedHealthcare and Optum, while Vertex is a biotech leader in cystic fibrosis therapies, notably Trikafta/Kaftrio.

Hims & Hers Health, UnitedHealth Group, and Vertex Pharmaceuticals are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare—including pharmaceutical and biotech firms, medical device and diagnostics makers, hospitals, clinics, and health insurers. Investors buy them to gain exposure to the healthcare sector’s growth opportunities from new drugs and technologies, while accepting sector-specific risks such as regulatory decisions, clinical trial results, and reimbursement changes. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Read Our Latest Research Report on HIMS

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Read Our Latest Research Report on UNH

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.